A Phase 3 interventional study of GFF MDI (PT003) and Placebo MDI in COPD, sponsored by Pearl Therapeutics, Inc.. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-19.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 47th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 3, and was the 45th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 122nd largest by enrollment of the 194 interventional ones that give a count, is one of 19 that started in 2015, is one of 76 in phase 3, and was the 164th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
Drug: GFF MDI (PT003)
Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
Drug: Placebo MDI
Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Drug: Spiriva® Respimat® (Tiotropium Bromide)
Drug pages: Glycopyrrolate · Formoterol
Also known as: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
Also known as: Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24
Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24
Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29
FEV1 AUC12-24
Normalized FEV1 AUC12-24
Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the evening dose on Day 29
FEV1 AUC0-12
Normalized FEV1 AUC0-12
Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the morning dose on Day 29
Peak Change From Baseline in FEV1 Evening
Peak Change From Baseline in FEV1 Evening
Time frame: Baseline and Day 29
Peak Change From Baseline in FEV1 Morning
Peak Change From Baseline in FEV1 Morning
Time frame: Baseline and Day 29
Morning Pre-Dose Trough FEV1 on Day 29
Morning Pre-Dose Trough FEV1 on Day 29
Time frame: Day 29
Morning Pre-Dose Trough FEV1 on Day 30
Morning Pre-Dose Trough FEV1 on Day 30
Time frame: Day 30
Peak Change From Baseline in IC (Inspiratory Capacity) Evening
Peak Change From Baseline in IC Evening
Time frame: Baseline and Day 29
Peak Change From Baseline in IC Morning
Peak Change From Baseline in IC Morning
Time frame: Baseline and Day 29
This study was conducted at 10 sites in the US from February 2015 to August 2015. The study was anticipated to run for approximately 9 months but not expected to exceed 12 months.
| Milestone | Overall Study |
|---|---|
| Started | 80 |
| Gff mdi 14.4/9.6 µg | 75 |
| Placebo mdi | 72 |
| Spiriva respimat 5 µg | 73 |
| Completed | 62 |
| Not completed | 18 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Physician decision | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Disc due to protocol-specified criteria | 6 |
Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24 | 0.192 (0.141 to 0.243) | 0.112 (0.061 to 0.162) | -0.072 (-0.123 to -0.022) |
Normalized FEV1 AUC12-24
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| FEV1 AUC12-24 | 0.159 (0.104 to 0.214) | 0.039 (-0.015 to 0.094) | -0.118 (-0.173 to -0.063) |
Normalized FEV1 AUC0-12
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| FEV1 AUC0-12 | 0.226 (0.175 to 0.276) | 0.178 (0.127 to 0.228) | -0.026 (-0.077 to 0.025) |
Peak Change From Baseline in FEV1 Evening
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Peak Change From Baseline in FEV1 Evening | 0.395 (0.334 to 0.456) | 0.230 (0.170 to 0.291) | 0.058 (-0.003 to 0.119) |
Peak Change From Baseline in FEV1 Morning
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Peak Change From Baseline in FEV1 Morning | 0.406 (0.351 to 0.462) | 0.325 (0.270 to 0.381) | 0.129 (0.073 to 0.185) |
Morning Pre-Dose Trough FEV1 on Day 29
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Morning Pre-Dose Trough FEV1 on Day 29 | 0.140 (0.095 to 0.185) | 0.097 (0.053 to 0.142) | -0.020 (-0.066 to 0.025) |
Morning Pre-Dose Trough FEV1 on Day 30
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Morning Pre-Dose Trough FEV1 on Day 30 | 0.129 (0.073 to 0.185) | 0.072 (0.015 to 0.128) | -0.073 (-0.130 to -0.017) |
Peak Change From Baseline in IC Evening
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Peak Change From Baseline in IC (Inspiratory Capacity) Evening | 0.421 (0.343 to 0.498) | 0.297 (0.221 to 0.372) | 0.109 (0.032 to 0.186) |
Peak Change From Baseline in IC Morning
| Liters | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Peak Change From Baseline in IC Morning | 0.454 (0.388 to 0.520) | 0.374 (0.307 to 0.440) | 0.206 (0.139 to 0.273) |
Collected over Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GFF MDI | — | 2/75 (2.7%) | 5/75 (6.7%) |
| Spiriva Respimat | — | 2/73 (2.7%) | 5/73 (6.8%) |
| Placebo | — | 2/72 (2.8%) | 6/72 (8.3%) |
| Event | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/75 | 0/73 | 1/72 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/75 | 0/73 | 1/72 |
| Small intestinal obstructionGastrointestinal disorders | 0/75 | 0/73 | 1/72 |
| Acute Myocardial InfarctionCardiac disorders | 0/75 | 1/73 | 0/72 |
| Chest painGeneral disorders | 0/75 | 1/73 | 0/72 |
| InfluenzaInfections and infestations | 1/75 | 0/73 | 0/72 |
| PneumoniaInfections and infestations | 1/75 | 0/73 | 0/72 |
| SepsisInfections and infestations | 1/75 | 0/73 | 0/72 |
| Event | GFF MDI | Spiriva Respimat | Placebo |
|---|---|---|---|
| VomitingGastrointestinal disorders | 0/75 | 3/73 | 0/72 |
| TremorNervous system disorders | 3/75 | 0/73 | 0/72 |
| HeadacheNervous system disorders | 1/75 | 1/73 | 2/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/75 | 1/73 | 2/72 |
| Back painMusculoskeletal and connective tissue disorders | 1/75 | 0/73 | 2/72 |
| FuruncleInfections and infestations | 0/75 | 2/73 | 0/72 |
| ConstipationGastrointestinal disorders | 2/75 | 0/73 | 1/72 |
MITT population was a subset of the ITT Population including subjects who received treatment and had post treatment efficacy data from at least 2 treatment periods and this population is used for baseline characteristics. Participant Flow includes all patients randomized, regardless of treatment received.
| Age, Continuous(Years) | All Subjects |
|---|---|
| Mean | 61.8 ± 9.1 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 48 |
| Male | 27 |
No study locations are listed for this record.
Ran from Feb 2015 to primary completion in Aug 2015, 6 months.
Results were first posted in Apr 2017, 1 year 8 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 6 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →